{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:07:54Z","timestamp":1780722474941,"version":"3.54.1"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre","doi-asserted-by":"publisher","award":["UMO-2015\/17\/B\/NZ7\/02937"],"award-info":[{"award-number":["UMO-2015\/17\/B\/NZ7\/02937"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ejps.2016.10.004","type":"journal-article","created":{"date-parts":[[2016,10,9]],"date-time":"2016-10-09T22:12:30Z","timestamp":1476051150000},"page":"362-372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Potential role of selected antiepileptics used in neuropathic pain as human GABA transporter isoform 1 (GAT1) inhibitors\u2014Molecular docking and pharmacodynamic studies"],"prefix":"10.1016","volume":"96","author":[{"given":"\u0141ukasz","family":"Fija\u0142kowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Sa\u0142at","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Podkowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Zar\u0119ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Nowaczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2016.10.004_bb0005","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1021\/jm00064a005","article-title":"The synthesis of novel GABA uptake inhibitors. 1. Elucidation of the structure-activity studies leading to the choice of (R)-1-[4, 4-bis (3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid (tiagabine) as an anticonvulsant drug candidate","volume":"36","author":"Andersen","year":"1993","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2016.10.004_bb0010","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1351\/PAC-REC-10-01-02","article-title":"Definition of the hydrogen bond (IUPAC Recommendations 2011)","volume":"83","author":"Arunan","year":"2011","journal-title":"Pure Appl. Chem."},{"key":"10.1016\/j.ejps.2016.10.004_bb0015","author":"ATC code"},{"key":"10.1016\/j.ejps.2016.10.004_bb0020","series-title":"Medicinal Chemistry Advances: Proceedings of the Seventh International Symposium on Medicinal Chemistry, Torremolinos, Spain 2\u20135 September 1980","first-page":"345","article-title":"Present knowledge of GABA receptor agonists","author":"Bartholini","year":"2016"},{"key":"10.1016\/j.ejps.2016.10.004_bb0025","first-page":"24","article-title":"Pain: its physiology and rationale for management Part III. Consequences of current concepts of pain mechanisms related to pain management","volume":"60","author":"Bishop","year":"1980","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2016.10.004_bb0030","series-title":"Gabab Receptor Pharmacology: A Tribute to Norman Bowery","author":"Blackburn","year":"2010"},{"key":"10.1016\/j.ejps.2016.10.004_bb9000","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/nar\/gkg095","article-title":"The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003","volume":"31","author":"Boeckmann","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejps.2016.10.004_bb0035","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0741-8329(99)00086-5","article-title":"Design and structure-activity relationship analysis of ligands of gamma-hydroxybutyric acid receptors","volume":"20","author":"Bourguignon","year":"2000","journal-title":"Alcohol"},{"key":"10.1016\/j.ejps.2016.10.004_bb0040","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/(SICI)1098-1128(199903)19:2<149::AID-MED3>3.0.CO;2-B","article-title":"3-Substituted GABA analogs with central nervous system activity: a review","volume":"19","author":"Bryans","year":"1999","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejps.2016.10.004_bb0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.drugalcdep.2004.10.002","article-title":"Comparison of the behavioral effects of gamma-hydroxybutyric acid (GHB) and its 4-methyl-substituted analog, gamma-hydroxyvaleric acid (GHV)","volume":"78","author":"Carter","year":"2005","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ejps.2016.10.004_bb0050","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1523\/JNEUROSCI.3364-04.2005","article-title":"GABA transporter deficiency causes tremor, ataxia, nervousness, and increased GABA-induced tonic conductance in cerebellum","volume":"25","author":"Chiu","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejps.2016.10.004_bb0055","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/sj.bjp.0702962","article-title":"Stereoselective central nervous system effects of the R-and S-isomers of the GABA uptake blocker N-(4, 4-di-(3-methylthien-2-yl) but-3-enyl) nipecotic acid in the rat","volume":"128","author":"Cleton","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2016.10.004_bb0060","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.brainresrev.2004.03.003","article-title":"GABA transporters in the mammalian cerebral cortex: localization, development and pathological implications","volume":"45","author":"Conti","year":"2004","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.ejps.2016.10.004_bb0065","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s11055-014-9982-6","article-title":"Antiepileptic drugs beyond epilepsy (use of anticonvulsants in the treatment of pain syndromes)","volume":"44","author":"Davydov","year":"2014","journal-title":"Neurosci. Behav. Physiol."},{"key":"10.1016\/j.ejps.2016.10.004_bb0070","series-title":"The Weak Hydrogen Bond: In Structural Chemistry And Biology","author":"Desiraju","year":"2001"},{"key":"10.1016\/j.ejps.2016.10.004_bb0075","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/sj.bjp.0702794","article-title":"Inhibition of uptake, steady-state currents, and transient charge movements generated by the neuronal GABA transporter by various anticonvulsant drugs","volume":"128","author":"Eckstein-Ludwig","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2016.10.004_bb0080","first-page":"385","article-title":"Synthetic analgesics. II. Dithienylbutenyl-and dithienylbutylamines","volume":"107","author":"Eddy","year":"1953","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2016.10.004_bb0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coph.2005.11.005","article-title":"Glutamate-and GABA-based CNS therapeutics","volume":"6","author":"Foster","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejps.2016.10.004_bb0090","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3892\/etm.2015.2577","article-title":"\u03b3-aminobutyric acid transporter-1 is involved in anxiety-like behaviors and cognitive function in knockout mice","volume":"10","author":"Gong","year":"2015","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.ejps.2016.10.004_bb0095","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.2174\/156802606778249801","article-title":"Structure-activity relationships of selective GABA uptake inhibitors","volume":"6","author":"Hog","year":"2006","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejps.2016.10.004_bb0100","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/ci3001277","article-title":"ZINC: a free tool to discover chemistry for biology","volume":"52","author":"Irwin","year":"2012","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejps.2016.10.004_bb0105","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2174\/1568007043336716","article-title":"GABA puts a stop to pain","volume":"3","author":"Jasmin","year":"2004","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.ejps.2016.10.004_bb0110","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/eujp.2001.0324","article-title":"Anticonvulsants in neuropathic pain: rationale and clinical evidence","volume":"6","author":"Jensen","year":"2002","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.ejps.2016.10.004_bb0115","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1527-3458.2003.tb00249.x","article-title":"Valproate past, present, and future","volume":"9","author":"Johannessen","year":"2003","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.ejps.2016.10.004_bb0120","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1021\/jm5015428","article-title":"A binding mode hypothesis of tiagabine confirms liothyronine effect on \u03b3-aminobutyric acid transporter 1 (GAT1)","volume":"58","author":"Jurik","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2016.10.004_bb0125","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000443173","article-title":"The neurobiological mechanisms of gamma-hydroxybutyrate (GHB) dependence and withdrawal and their clinical relevance","volume":"73","author":"Kamal","year":"2016","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.ejps.2016.10.004_bb0130","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1016\/j.bmc.2013.06.038","article-title":"2-Substituted 4-hydroxybutanamides as potential inhibitors of \u03b3-aminobutyric acid transporters mGAT1\u2013mGAT4: synthesis and biological evaluation","volume":"21","author":"Kowalczyk","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2016.10.004_bb0135","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejmech.2014.06.024","article-title":"Synthesis, biological evaluation and structure\u2013activity relationship of new GABA uptake inhibitors, derivatives of 4-aminobutanamides","volume":"83","author":"Kowalczyk","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2016.10.004_bb0140","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1124\/pr.108.000869","article-title":"SLC6 neurotransmitter transporters: structure, function, and regulation","volume":"63","author":"Kristensen","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejps.2016.10.004_bb0145","first-page":"RA1","article-title":"Targets for antiepileptic drugs in the synapse","volume":"13","author":"Landmark","year":"2006","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.ejps.2016.10.004_bb0150","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/B978-0-444-53480-4.00034-5","article-title":"Painful neuropathy: mechanisms","volume":"126","author":"Lee-Kubli","year":"2013","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.ejps.2016.10.004_bb0155","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.seizure.2011.01.003","article-title":"Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs","volume":"20","author":"L\u00f6scher","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.ejps.2016.10.004_bb0160","series-title":"Handbook of Neurochemistry and Molecular Neurobiology","first-page":"285","article-title":"Functional and pharmacological aspects of GABA transporters","author":"Madsen","year":"2007"},{"key":"10.1016\/j.ejps.2016.10.004_bb0165","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.pharmthera.2009.11.007","article-title":"Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs","volume":"125","author":"Madsen","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2016.10.004_bb0170","first-page":"683","article-title":"Zonisamide: a new antiepileptic drug","volume":"55","author":"Ma\u0142ek","year":"2003","journal-title":"Pol. J. Pharmacol."},{"key":"10.1016\/j.ejps.2016.10.004_bb0175","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1007\/s11064-014-1254-x","article-title":"GABA pharmacology: the search for analgesics","volume":"39","author":"McCarson","year":"2014","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejps.2016.10.004_bb0180","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1111\/j.1528-1157.1999.tb02087.x","article-title":"Basic mechanisms of gabitril (tiagabine) and future potential developments","volume":"40","author":"Meldrum","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2016.10.004_bb0185","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","article-title":"Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function","volume":"19","author":"Morris","year":"1998","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejps.2016.10.004_bb0190","first-page":"1","article-title":"Recent advances in use of semicarbazones as anticonvulsant agents: a review","volume":"2","author":"Nain","year":"2014","journal-title":"J. Biomed. Ther. Sci."},{"key":"10.1016\/j.ejps.2016.10.004_bb0195","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.pain.2011.02.051","article-title":"Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation","volume":"152","author":"Nassini","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.ejps.2016.10.004_bb0200","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1021\/jm00112a032","article-title":"GABA-uptake inhibitors: construction of a general pharmacophore model and successful prediction of a new representative","volume":"34","author":"N'Goka","year":"1991","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2016.10.004_bb0205","first-page":"167","article-title":"GHB: an important pharmacologic and clinical update","volume":"4","author":"Okun","year":"2001","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejps.2016.10.004_bb0210","first-page":"192","article-title":"Zonisamide: a new antiepileptic drug","volume":"22","author":"Oommen","year":"1999","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ejps.2016.10.004_bb0215","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.pain.2008.03.017","article-title":"Glutamate receptor ligands attenuate allodynia and hyperalgesia and potentiate morphine effects in a mouse model of neuropathic pain","volume":"139","author":"Osikowicz","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.ejps.2016.10.004_bb0220","series-title":"Antiepileptic Drug Interactions: A Clinical Guide","author":"Patsalos","year":"2012"},{"key":"10.1016\/j.ejps.2016.10.004_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1744-8069-7-29","article-title":"Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice","volume":"7","author":"Renn","year":"2011","journal-title":"Mol. Pain"},{"key":"10.1016\/j.ejps.2016.10.004_bb0230","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1734-1140(12)70877-0","article-title":"Synthesis and pharmacological properties of new GABA uptake inhibitors","volume":"64","author":"Sa\u0142at","year":"2012","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejps.2016.10.004_bb0235","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pbb.2014.03.025","article-title":"Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice","volume":"122","author":"Sa\u0142at","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejps.2016.10.004_bb0240","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1517\/13543784.2014.956079","article-title":"Zucapsaicin for the treatment of neuropathic pain","volume":"23","author":"Sa\u0142at","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejps.2016.10.004_bb0245","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1517\/13543784.2014.916688","article-title":"New investigational drugs for the treatment of neuropathic pain","volume":"23","author":"Sa\u0142at","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejps.2016.10.004_bb0250","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.pharep.2014.11.003","article-title":"Anticonvulsant active inhibitor of GABA transporter subtype 1, tiagabine, with activity in mouse models of anxiety, pain and depression","volume":"67","author":"Sa\u0142at","year":"2015","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejps.2016.10.004_bb0255","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.pharep.2015.04.018","article-title":"The effect of GABA transporter 1 (GAT1) inhibitor, tiagabine, on scopolamine-induced memory impairments in mice","volume":"67","author":"Sa\u0142at","year":"2015","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejps.2016.10.004_bb0260","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.neuropharm.2015.07.037","article-title":"Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: role of activity at NMDA receptor","volume":"99","author":"Sa\u0142at","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejps.2016.10.004_bb0265","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.yebeh.2011.03.037","article-title":"Antiepileptic drug discovery: does mechanism of action matter?","volume":"21","author":"Schmidt","year":"2011","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.ejps.2016.10.004_bb0270","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0166-4328(02)00008-6","article-title":"Tiagabine, a \u03b3-amino-butyric acid transporter inhibitor impairs spatial learning of rats in the Morris water-maze","volume":"133","author":"Schmitt","year":"2002","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejps.2016.10.004_bb0275","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1007\/s11064-014-1263-9","article-title":"The GABA synapse as a target for antiepileptic drugs: a historical overview focused on GABA transporters","volume":"39","author":"Schousboe","year":"2014","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejps.2016.10.004_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2014.00161","article-title":"Structure, function, and plasticity of GABA transporters","volume":"8","author":"Scimemi","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ejps.2016.10.004_bb0285","series-title":"Pharmacological profile of the GABA-transaminase inhibitor Vigabatrin","author":"Sherif","year":"2015"},{"key":"10.1016\/j.ejps.2016.10.004_bb0290","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.coph.2005.11.003","article-title":"The mechanisms of action of gabapentin and pregabalin","volume":"6","author":"Sills","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejps.2016.10.004_bb0295","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/0960327115579206","article-title":"Review of toxicity and trends in the use of tiagabine as reported to US poison centers from 2000 to 2012","volume":"35","author":"Spiller","year":"2016","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.ejps.2016.10.004_bb0300","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1528-1157.1995.tb02576.x","article-title":"A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor","volume":"36","author":"Suzdak","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2016.10.004_bb0305","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1254\/jphs.08032FP","article-title":"Zonisamide suppresses pain symptoms of formalin-induced inflammatory and streptozotocin-induced diabetic neuropathy","volume":"107","author":"Tanabe","year":"2008","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejps.2016.10.004_bb0310","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1002\/jnr.21786","article-title":"Pain relief by gabapentin and pregabalin via supraspinal mechanisms after peripheral nerve injury","volume":"86","author":"Tanabe","year":"2008","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ejps.2016.10.004_bb0315","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0920-1211(97)00084-3","article-title":"A summary of mechanistic hypotheses of gabapentin pharmacology","volume":"29","author":"Taylor","year":"1998","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejps.2016.10.004_bb0320","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1016\/j.bmc.2015.03.060","article-title":"Structure activity relationship of selective GABA uptake inhibitors","volume":"23","author":"Vogensen","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2016.10.004_bb0325","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.yebeh.2013.05.006","article-title":"Tiagabine in clinical practice: effects on seizure control and behavior","volume":"28","author":"Vossler","year":"2013","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.ejps.2016.10.004_bb0330","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.2174\/092986711797200408","article-title":"Evaluation of anticonvulsants for possible use in neuropathic pain","volume":"18","author":"Waszkielewicz","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejps.2016.10.004_bb0335","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/cmdc.201500534","article-title":"Different binding modes of small and large binders of GAT1","volume":"11","author":"Wein","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejps.2016.10.004_bb0340","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1042\/bst0290736","article-title":"Upregulation of \u03b3-aminobutyric acid transporter expression: role of alkylated \u03b3-aminobutyric acid derivatives","volume":"29","author":"Whitworth","year":"2001","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ejps.2016.10.004_bb0345","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/sj.bjp.0706310","article-title":"Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain","volume":"146","author":"Winkler","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2016.10.004_bb0350","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.neuroscience.2011.12.023","article-title":"Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel","volume":"203","author":"Xiao","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejps.2016.10.004_bb0355","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nature03978","article-title":"Crystal structure of a bacterial homologue of Na&plus;\/Cl\u2013dependent neurotransmitter transporters","volume":"437","author":"Yamashita","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2016.10.004_bb0360","first-page":"1","article-title":"GABA and glutamate transporters in brain","volume":"4","author":"Zhou","year":"2014","journal-title":"Front. Endocrinol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098716304274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098716304274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T20:22:11Z","timestamp":1536351731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098716304274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":73,"alternative-id":["S0928098716304274"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2016.10.004","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential role of selected antiepileptics used in neuropathic pain as human GABA transporter isoform 1 (GAT1) inhibitors\u2014Molecular docking and pharmacodynamic studies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2016.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}